LongueVue Capital, a New Orleans-based private equity firm focused on providing growth capital to middle-market companies, has made an investment in Summit Clinical Research LLC, an integrated research organization (IRO).
Summit, based in San Antonio, Texas, manages over 100 clinical trial sites globally, looking to improve trial enrollment, quality and outcomes in complex clinical trials. The company is focused on complex indications including hepatology, specifically non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. The investment works to provide human capital and financial capital to drive Summit’s growth.
“After working for 30+ years leading clinical operations, I have confidence in Summit’s ability to efficiently and cost-effectively drive superior clinical trial outcomes for sponsors, especially in NASH trials, which are notoriously difficult to recruit and retain patients,” comments Adrian Otte, LongueVue Capital’s life science operating partner. “Summit is well-positioned to continue to capitalize on the strong tailwinds as a thought leader in the sector, and I am excited to work closely with the Summit team to enhance its existing offerings and drive sustainable growth.”
LVC’s legal counsel was provided by Norton Rose Fulbright LLP.